MTSR Metsera, Inc. NASDAQ pre-market $70.50 on 20 Mar 2026: earnings week focus

MTSR stock is trading at $70.50 pre-market on 20 Mar 2026 as investors position ahead of Metsera, Inc.’s scheduled earnings announcement on 25 Mar 2026. Volume is elevated at 27,874,411.00 shares, well above the 50-day average of 3,501,952.00, signaling heavy interest. Market participants will watch clinical updates, cash runway metrics and any guidance that could reshape the biotech valuation.

MTSR stock: earnings calendar and expectations

Metsera (MTSR) reports results after the close on 25 Mar 2026. Analysts and investors will focus on cash burn, R&D updates and any timeline for late-stage trials. One clear catalyst is commentary on MET-097i and MET-233i enrollment and safety that could move the stock sharply.

MTSR stock: recent price action and liquidity

Shares opened at $70.74 and trade between $70.13 and $70.76 in pre-market. The stock shows a year high of $83.86 and a year low of $12.30, reflecting a volatile climb since the IPO. Relative volume sits at 7.96, and the 50-day average price is $53.47, which underlines the recent momentum.

Fundamentals and valuation for Metsera, Inc. (MTSR)

Metsera’s market cap is $7,429,021,325.00 with 105,376,189.00 shares outstanding. Trailing EPS is -2.99 and the trailing PE shows -23.58, reflecting a clinical-stage loss profile. Cash per share is $4.27 and the current ratio is 4.25, indicating a solid near-term liquidity position.

Clinical pipeline, sector placement and catalysts

Metsera operates in the Biotechnology industry within the Healthcare sector. Key programs include MET-097i and MET-233i for obesity and metabolic disease. Positive trial readouts or faster enrollment can drive upside, while safety setbacks or slower trials pose the main downside risks.

Technical indicators, trading signals and Meyka AI grade

Short-term technicals show ATR at 0.65 and Keltner channels centered at $70.50. On liquidity metrics, the company posts average volume of 3,501,952.00 and large intraday flows today. Meyka AI rates MTSR with a score out of 100: Score: 66.50 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. These grades are not guaranteed and are not investment advice.

Analyst outlook and price target scenarios

Public analyst coverage is limited since the 2025 IPO, so scenario work matters more than consensus. A conservative near-term target is $90.00, reflecting modest clinical progress. Meyka AI’s 12-month model projects $148.30, and a three-year scenario aligns with $297.56 if programs succeed. All targets depend on trial outcomes and funding.

Final Thoughts

Key takeaways for MTSR stock: Metsera trades at $70.50 pre-market on 20 Mar 2026 with heavy volume ahead of the 25 Mar 2026 earnings and clinical updates. Fundamentals show a clinical-stage loss profile (EPS -2.99) but healthy liquidity (current ratio 4.25, cash per share $4.27). Meyka AI’s forecast model projects $148.30, implying an upside of 110.33% versus the current price of $70.50. The stock grade is B (HOLD), reflecting balanced upside from pipeline success and downside from clinical or operational setbacks. Investors should watch the earnings commentary, trial readouts and any capital raise news. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.